221.20
+3.7(+1.70%)
Currency In GBp
Sector
Healthcare
Industry
Biotechnology
Employees
25
First IPO Date
November 17, 2015
| Name | Title | Pay | Year Born |
| Dr. Juho Markku Jalkanen M.D., MSc, Ph.D. | Founder, Chief Executive Officer & Director | 185,399 | 1978 |
| Mr. Yrjö Erik Kristian Wichmann M.Sc (Econ.), M.Sc. | Chief Financial Officer | 382,628 | 1958 |
| Mr. Vesa Karvonen L.L.M. | General Counsel | 0 | 1972 |
| Dr. Maija Hollmen Ph.D. | Chief Scientific Officer | 0 | N/A |
| Dr. Petri Bono M.D., Ph.D. | Chief Medical Officer | 0 | 1970 |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
